EP 3843761 A4 20220608 - CHIMERIC ONCOLYTIC HERPESVIRUS THAT STIMULATE AN ANTITUMOR IMMUNE RESPONSE
Title (en)
CHIMERIC ONCOLYTIC HERPESVIRUS THAT STIMULATE AN ANTITUMOR IMMUNE RESPONSE
Title (de)
CHIMÄRES ONKOLYTISCHES HERPESVIRUS, DAS EINE ANTITUMORIMMUNREAKTION STIMULIERT
Title (fr)
HERPÈSVIRUS ONCOLYTIQUE CHIMÉRIQUE QUI STIMULE UNE RÉPONSE IMMUNITAIRE ANTITUMORALE
Publication
Application
Priority
- US 201862725809 P 20180831
- US 2019049047 W 20190830
Abstract (en)
[origin: WO2020047398A1] A chimeric oncolytic virus is described that includes a herpesvirus having a modified nucleic acid sequence, including a modification of the herpesvirus gamma (1)34.5 gene (γ134.5) or a nucleic acid with at least about 70% homology to the γ134.5 gene that reduces its expression; a second viral nucleic acid sequence encoding a PKR evasion protein that does not cause virulence; and a third nucleic acid sequence encoding a tumor-associated antigen. Methods of using the chimeric oncolytic virus to treat subjects having cancer, or to vaccinate subjects at risk of developing cancer, are also described.
IPC 8 full level
A61K 35/76 (2015.01); A61P 35/04 (2006.01); C12N 5/02 (2006.01); C12N 7/01 (2006.01); C12N 15/00 (2006.01)
CPC (source: EP IL KR)
A61K 35/763 (2013.01 - EP IL KR); A61P 35/00 (2017.12 - KR); A61P 35/04 (2017.12 - EP IL); C07K 14/4748 (2013.01 - EP IL KR); C07K 14/705 (2013.01 - EP IL); C12N 7/00 (2013.01 - KR); C12N 15/86 (2013.01 - EP IL KR); C12Y 207/10 (2013.01 - EP IL); C12N 2710/16132 (2013.01 - KR); C12N 2710/16632 (2013.01 - EP IL KR); C12N 2710/16643 (2013.01 - EP IL KR)
Citation (search report)
- [A] GHONIME MOHAMMED G. ET AL: "Chimeric HCMV/HSV-1 and [Delta][gamma]134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory", TRANSLATIONAL ONCOLOGY, vol. 11, no. 1, 1 February 2018 (2018-02-01), United States, pages 86 - 93, XP055915040, ISSN: 1936-5233, DOI: 10.1016/j.tranon.2017.10.005
- [T] GHONIME MOHAMMED G ET AL: "Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, no. 10, 26 August 2021 (2021-08-26), pages e002939, XP055915209, Retrieved from the Internet <URL:https://jitc.bmj.com/content/jitc/9/10/e002939.full.pdf?with-ds=yes> DOI: 10.1136/jitc-2021-002939
- See references of WO 2020047398A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2020047398 A1 20200305; WO 2020047398 A9 20200430; AU 2019333181 A1 20210318; BR 112021003807 A2 20210518; BR 112021003807 A8 20220419; CA 3110406 A1 20200305; CN 113396217 A 20210914; EP 3843761 A1 20210707; EP 3843761 A4 20220608; IL 281085 A 20210429; JP 2021534786 A 20211216; KR 20210053923 A 20210512; SG 11202101829U A 20210330
DOCDB simple family (application)
US 2019049047 W 20190830; AU 2019333181 A 20190830; BR 112021003807 A 20190830; CA 3110406 A 20190830; CN 201980072185 A 20190830; EP 19855584 A 20190830; IL 28108521 A 20210224; JP 2021510715 A 20190830; KR 20217009134 A 20190830; SG 11202101829U A 20190830